OIG says Medicare Part D paying for invalid, illegal prescriptions

Pills

The Office of the Inspector General says criminals are exploiting weaknesses in the Medicare Part D program to obtain false prescriptions for schedule II medications, the Associated Press reports.

According to an examination of the Part D program by the OIG, Medicare has been unable to verify all of the prescriptions it pays for through the Part D program. Although pharmacists are required to enter an identifier number and submit it to the Centers for Medicare and Medicaid Services every time they fill a prescription, in many instances a dummy number is used or it is left blank.

"It's similar to placing a combination lock on a gate to protect what's inside but then allowing any combination to open the gate,'' said Robert Vito, a regional inspector general for the U.S. Department of Health and Human Services.

Product Spotlight

Top-Rated Mobile App for Health Insurance Members

Zipari’s Mobile App is the smarter, easier, and better way for payers to engage members on the go and directly in the palm of their hands. Members can find the right doctors, receive notifications, send messages, view claims, track spending, talk to a nurse, download ID card, and more. It’s ready to install and launch in a few months.

The amount of drugs purchased by CMS with no or false identifiers was relatively small--$20.6 million in 2007, out of a total of $1.6 billion paid for schedule II drugs. Such items include narcotics that are widely trafficked illegally, like oxycodone and methadone.

CMS officials have agreed to fix the system and require an identifier or a Drug Enforcement Administration number to pay for a prescription.

For more:
- read the OIG report (.pdf)

Suggested Articles

Oak Street Health officially went pubilc on Thursday with a $328 million initial public offering.

Two doctors would like to see a practice and policy "reset" post-COVID to help permanently reduce administrative headaches for physicians.

Ginger banked a $50 million funding round backed by the venture arms of Cigna and Kaiser Permanente. Here's how it plans to use the financing.